Rosen Law Firm Investigates Potential Claims for Immutep Ltd. Investors Following Major Stock Drop

Legal Investigation Update: Immutep Ltd.

Rosen Law Firm, a prominent global legal practice focused on protecting investor rights, has initiated an investigation into potential securities fraud regarding Immutep Ltd. (NASDAQ: IMMP). This inquiry comes in light of substantial allegations that the company may have disseminated misleading business information to the public, which has had significant repercussions for its stock performance.

Background of the Investigation

On March 13, 2026, Immutep issued a press release disclosing that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study—investigating eftilagimod alfa in patients with non-small cell lung cancer—recommended halting the trial due to a planned interim futility analysis. Following this declaration, the share price of Immutep's American Depositary Receipt (ADR) plummeted by $2.28, marking an 82.6% drop to a closing price of just $0.48.

Such drastic fluctuations in stock value raise concerns regarding the accuracy of Immutep's previously communicated data and intentions, thus prompting Rosen Law Firm's investigation. Investors who acquired shares of Immutep during this turbulent period may qualify for compensation under a contingency fee arrangement, meaning there would be no out-of-pocket costs to pursue the claim.

Steps for Investors

Investors with an interest in joining the potential class action are urged to act promptly. Rosen Law Firm has established a straightforward process for registration. Interested individuals can easily submit their information via the firm's website or contact Phillip Kim, Esq. directly at 866-767-3653 or through email for comprehensive details on how to proceed.

This investigation aims to gather those who have suffered losses attributed to the misleading statements potentially made by Immutep. Rosen Law Firm emphasizes the importance of selecting experienced legal representation, as many firms touting involvement might lack the necessary qualifications and proven track records in securities litigation.

Track Record of Rosen Law Firm

Rosen Law Firm is recognized for its exceptional performance in investor rights cases, having achieved the largest securities class action settlement against a Chinese company. The firm has been ranked as a leading entity in securities class action settlements since 2013. In 2019 alone, it secured over $438 million for its clients. Founding partner Laurence Rosen has notably received accolades, including recognition as a Titan of the Plaintiffs' Bar by Law360.

Furthermore, Rosen Law Firm's attorneys have been acknowledged by prestigious bodies such as Lawdragon and Super Lawyers for their contributions to securities litigation.

Investors are encouraged to keep up with updates from the firm via social media channels, including LinkedIn, Twitter, and Facebook, as developments unfold regarding this investigation.

In summary, if you believe you may have been impacted by Immutep's recent stock fluctuations and the surrounding alleged misinformation, take advantage of Rosen Law Firm's investigative efforts now. Your chances of receiving compensation could hinge on your prompt action.

Conclusion

In the aftermath of troubling news from Immutep, it is essential for investors to remain vigilant and informed. Rosen Law Firm stands as a dedicated advocate for those who have suffered financial losses due to misleading securities practices, reinforcing the importance of investor awareness and proper legal counsel in navigating such complex circumstances.